LTRN Stock Analysis: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$3.40
-0.34 (-9.09%)
▼
5d:
+2.72%
30d:
+52.47%
90d:
+20.57%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: LTRN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: LTRN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $3.40, which is considered slightly high relative to its 30-day fair value range of $2.16 to $3.41.
Technical Outlook: Technically, LTRN is in a downtrend. Immediate support is located at $3.02, while resistance sits at $3.98. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: LTRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+488.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, LTRN is in a downtrend. Immediate support is located at $3.02, while resistance sits at $3.98. Short-term momentum is weak, with the stock down 9.1% recently.
Market Sentiment: LTRN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.00 (+488.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.16 -
$3.41
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-9.1%)
- BULLISH: Trading 488.2% below Wall St target ($20.00)
Trading Range Analysis
30-Day Trading Range
$2.16 -
$3.41
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.77
(22.6%)
Support & Resistance Levels
Support Level
$3.03
Resistance Level
$3.98
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.68
Wall Street Target
$20.00
(+488.2%)
Share & Embed Analysis
Last updated: June 04, 2026 1:58 AM ET
Data refreshes hourly during market hours. Next update: 2:58 AM
Data refreshes hourly during market hours. Next update: 2:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 54 HOLD |
